EGFR-exon 20 mutations
Friday 28 June 2013
EGFR-exon 20 insertions
In contrast to other primary epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas, insertions in exon 20 of EGFR have been generally associated with resistance to EGFR-tyrosine kinase inhibitors.
EGFR exon 20 insertion testing identifies a distinct subset of lung adenocarcinomas, accounting for at least 9% of all EGFR-mutated cases, representing the third most common type of EGFR mutation after exon 19 deletions and L858R.
Insertions are structurally heterogeneous with potential implications for response to EGFR inhibitors.
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M. Mol Cancer Ther. 2013 Feb;12(2):220-9. doi:10.1158/1535-7163.MCT-12-0620 . PMID: #23371856#